Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) announced results from a Phase 2 trial showing its investigational ZORYVE cream improved atopic dermatitis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE